![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: SP140 |
Gene summary for SP140 |
![]() |
Gene information | Species | Human | Gene symbol | SP140 | Gene ID | 11262 |
Gene name | SP140 nuclear body protein | |
Gene Alias | LYSP100 | |
Cytomap | 2q37.1 | |
Gene Type | protein-coding | GO ID | GO:0006139 | UniProtAcc | B4DVW8 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
11262 | SP140 | LZE4T | Human | Esophagus | ESCC | 2.92e-03 | 3.21e-01 | 0.0811 |
11262 | SP140 | LZE6T | Human | Esophagus | ESCC | 3.33e-05 | 3.20e-01 | 0.0845 |
11262 | SP140 | P22T-E | Human | Esophagus | ESCC | 1.62e-13 | 2.36e-01 | 0.1236 |
11262 | SP140 | P47T-E | Human | Esophagus | ESCC | 5.79e-16 | 2.75e-01 | 0.1067 |
11262 | SP140 | P52T-E | Human | Esophagus | ESCC | 1.35e-23 | 6.78e-01 | 0.1555 |
11262 | SP140 | P80T-E | Human | Esophagus | ESCC | 1.83e-19 | 6.20e-01 | 0.155 |
11262 | SP140 | HCC1_Meng | Human | Liver | HCC | 3.46e-02 | 1.92e-02 | 0.0246 |
11262 | SP140 | HCC5 | Human | Liver | HCC | 4.83e-09 | 1.61e+00 | 0.4932 |
11262 | SP140 | S028 | Human | Liver | HCC | 1.88e-11 | 4.79e-01 | 0.2503 |
11262 | SP140 | S029 | Human | Liver | HCC | 1.85e-14 | 6.00e-01 | 0.2581 |
Page: 1 |
![]() |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
Page: 1 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
SP140 | SNV | Missense_Mutation | c.2208N>T | p.Lys736Asn | p.K736N | Q13342 | protein_coding | deleterious(0.05) | benign(0.007) | TCGA-AP-A0LM-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | cisplatin | SD | |
SP140 | SNV | Missense_Mutation | novel | c.1393N>A | p.Pro465Thr | p.P465T | Q13342 | protein_coding | tolerated(0.07) | possibly_damaging(0.59) | TCGA-AP-A1DK-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
SP140 | SNV | Missense_Mutation | rs778717233 | c.1999N>T | p.Arg667Cys | p.R667C | Q13342 | protein_coding | deleterious(0.01) | benign(0.092) | TCGA-AP-A1E0-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | paclitaxel | SD |
SP140 | SNV | Missense_Mutation | c.1994N>T | p.Arg665Ile | p.R665I | Q13342 | protein_coding | deleterious(0) | possibly_damaging(0.781) | TCGA-AX-A0J0-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
SP140 | SNV | Missense_Mutation | c.2325N>T | p.Glu775Asp | p.E775D | Q13342 | protein_coding | deleterious(0.01) | probably_damaging(0.952) | TCGA-AX-A0J0-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
SP140 | SNV | Missense_Mutation | novel | c.887N>G | p.Asp296Gly | p.D296G | Q13342 | protein_coding | tolerated(0.3) | benign(0.049) | TCGA-AX-A1CE-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unspecific | Paclitaxel | SD |
SP140 | SNV | Missense_Mutation | novel | c.715C>T | p.Pro239Ser | p.P239S | Q13342 | protein_coding | tolerated(0.06) | benign(0.093) | TCGA-AX-A2HC-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | paclitaxel | PD |
SP140 | SNV | Missense_Mutation | novel | c.919G>T | p.Val307Phe | p.V307F | Q13342 | protein_coding | tolerated(0.49) | benign(0.015) | TCGA-AX-A2HC-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | paclitaxel | PD |
SP140 | SNV | Missense_Mutation | c.1018C>T | p.Pro340Ser | p.P340S | Q13342 | protein_coding | tolerated(0.06) | benign(0.283) | TCGA-AX-A2HC-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | paclitaxel | PD | |
SP140 | SNV | Missense_Mutation | novel | c.1417G>A | p.Glu473Lys | p.E473K | Q13342 | protein_coding | tolerated(0.11) | benign(0.003) | TCGA-AX-A2HC-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | paclitaxel | PD |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |